Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2.

导出 OA

翻译打印收藏纠错

作者： Claire N,Harrison ^[1] ; Alessandro M,Vannucchi ^[2] ; Christian,Recher ^[3] ; Francesco,Passamonti ^[4] ; Aaron T,Gerds ^[5] ; Juan Carlos,Hernandez-Boluda ^[6] ; Abdulraheem,Yacoub ^[7] ; Shireen,Sirhan ^[8] ; Catherine,Ellis ^[9] ; Bharat,Patel ^[9] ; Bryan,Strouse ^[9] ; Uwe,Platzbecker ^[10]

作者单位： Guy's and St Thomas' NHS Foundation Trust, Great Maze Pond, London, SE1 9RT, UK. claire.harrison@gstt.nhs.uk. ^[1] University of Florence, Florence, Italy. ^[2] University Hospital Center (CHU) of Toulouse, Toulouse, France. ^[3] Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Dipartimento di Oncologia ed Onco-Ematologia, Università degli Studi di Milano, Milan, Italy. ^[4] Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA. ^[5] Hospital Clìnico de Valencia-INCLIVA, University of Medicine, Valencia, Spain. ^[6] University of Kansas, Kansas City, KS, USA. ^[7] Jewish General Hospital, McGill University, Montreal, QC, Canada. ^[8] GSK plc, Philadelphia, PA, USA. ^[9] University Hospital Leipzig, Leipzig, Germany. ^[10]

关键词 Anemia Anemia?supportive therapy Erythropoiesis-stimulating agents Hemoglobin Momelotinib Myelofibrosis Red blood cell transfusions Ruxolitinib Transfusion independence